RecruitingPhase 2NCT05672108

Phase II Trial of Lung Chemoemobolization

Sponsor

City of Hope Medical Center

Enrollment

30 participants

Start Date

May 12, 2023

Study Type

INTERVENTIONAL

Conditions

Sarcoma Colon Cancer Lung Non-Small Cell Carcinoma Mediastinal Neoplasm Pleural Neoplasm Lung Metastases From Any Primary Endobronchial Metastases

Summary

This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests lung chemoembolization — a procedure where chemotherapy is delivered directly into the blood vessels feeding lung tumors — in patients with lung cancer or lung metastases that are no longer responding to systemic (whole-body) treatment. The approach aims to deliver high-dose chemotherapy locally with fewer systemic side effects. **You may be eligible if...** - You are 18 or older - You have lung cancer or cancer that has spread to the lungs, with most of your active tumor in the chest - Your cancer is progressing on systemic therapy or you cannot tolerate systemic treatment - Your tumor cannot be removed surgically or treated with ablation or focused radiation **You may NOT be eligible if...** - Your general health is significantly impaired (ECOG score above 2) - Your oxygen levels are low (below 92% on room air) - Your lung function is severely reduced (FEV1 below 60%) - Your tumor is not measurable Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.